

## Press Release

Stockholm, Sweden, May 25, 2023

### Mendus to participate in upcoming conferences in June 2023

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:

#### Redeye Growth Day

Virtual, June 1, 2023

Mendus CEO Erik Manting will participate in a live Q&A session on June 1<sup>st</sup>. Further details including the on-demand corporate presentation are available via:

<https://www.redeye.se/events/871323/redeye-growth-day>

#### BIO International Convention

Boston, USA, June 5-8, 2023

Erik Manting, CEO of Mendus, will attend the conference.

<https://www.bio.org/events/bio-international-convention>

#### EHA2023 Hybrid Congress

Frankfurt, Germany, and Virtual, June 8-11, 2023

Mendus to present updates on immunomonitoring data from ADVANCE II trial and progress on the development of its NK cell therapy program.

<https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/>

#### FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting  
Chief Executive Officer  
E-mail: [ir@mendus.com](mailto:ir@mendus.com)

INVESTOR RELATIONS  
Corey Davis  
LifeSci Advisors, LLC  
Telephone: + 1 212-915-2577  
E-mail: [cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

MEDIA RELATIONS  
Mario Brkulj  
Valency Communications  
Telephone: +49 160 9352 9951  
E-mail: [mbrkulj@valencycomms.eu](mailto:mbrkulj@valencycomms.eu)

#### ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <http://www.mendus.com/>